Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 57, Issue 10


Evaluation of the possible interference of abiraterone therapy on testosterone immunoassay

Ruggero Dittadi
  • Corresponding author
  • Laboratory Medicine Department, Ospedale dell’Angelo, ULSS 3 Serenissima, Via Paccagnella 11, 30174 Mestre (Venice), Italy
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Vania Polesello
  • Laboratory Medicine Department, Ospedale dell’Angelo, ULSS 3 Serenissima, Mestre (Venice), Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Andrea Zivi
  • Medical Oncology Department, AOUI Verona, Verona, Italy
  • Section of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Paolo Carraro
  • Laboratory Medicine Department, Ospedale dell’Angelo, ULSS 3 Serenissima, Mestre (Venice), Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-03-15 | DOI: https://doi.org/10.1515/cclm-2018-1288


  • 1.

    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.PubMedCrossrefGoogle Scholar

  • 2.

    Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 3.

    Attard G, Reid AH, A’Hern R, Parker C, Ommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742–8.Web of SciencePubMedCrossrefGoogle Scholar

  • 4.

    O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317–25.PubMedCrossrefGoogle Scholar

  • 5.

    Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother 2018;101:211–8.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 6.

    Fairfax BP, Morgan RD, Protheroe A, Shine B, James T. Abiraterone acetate: a potential source of interference in testosterone assays. Clin Chem Lab Med 2018;56:e138–40.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 7.

    Dittadi R, Matteucci M, Meneghetti E, Ndreu R. Reassessment of the access testosterone chemiluminescence assay and comparison with LC-MS method. J Clin Lab Anal 2018;32:e22286.Web of ScienceCrossrefGoogle Scholar

  • 8.

    Meani D, Solarić M, Visapää H, Rosén RM, Janknegt R, Soče M. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Ther Adv Urol 2017;10:51–63.PubMedWeb of ScienceGoogle Scholar

  • 9.

    Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563–71.CrossrefWeb of SciencePubMedGoogle Scholar

  • 10.

    Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, RaynaudF, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481–8.CrossrefWeb of SciencePubMedGoogle Scholar

About the article

Received: 2018-12-04

Accepted: 2019-02-16

Published Online: 2019-03-15

Published in Print: 2019-09-25

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 10, Pages e253–e254, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-1288.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in